North America Benign Prostatic Hyperplasic Devices Market Forecast to 2028 - COVID-19 Impact and Regional Analysis - by Product, Procedure Type, and End User

The benign prostatic hyperplasic devices market in North America is expected to grow from US$ 863.12 million in 2022 to US$ 1,349.19 million by 2028; it is estimated to grow at a CAGR of 7.7% from 2022 to 2028.

Benign prostatic hyperplasia (BPH) is a prostate enlargement caused by excessive cell growth in the prostate. This noncancerous prostate condition is usually not fatal. Being benign, the condition does not involve metastasis to other body parts. BPH is not associated with the risk of prostate cancer; moreover, unless it manifests symptoms, BPH isn't considered a health issue. Almost all men are likely to have some prostate growth by the time they turn 70. Aging, abdominal obesity, and insufficient physical exercise raise the risk of developing BPH. According to the National Center for Biotechnology Information (NCBI), BPH is one of the most common disorders in older men and the leading cause of lower urinary tract symptoms (LUTS). After the age of 40, the prevalence of BPH rises, reaching a peak of 60% by the age of 90. Many autopsy studies suggest that the histological prevalence of BPH is 8%, 50%, and 80% in the fourth, sixth, and ninth decades of the life of a man, respectively. Old age has also been shown to be a risk factor for the onset and progression of clinical BPH in observational studies conducted in the US. According to statistics from the Krimpen and Baltimore Longitudinal Study of Aging, the prostate grows at a rate of 2.0-2.5% per year in elderly men. Continued prostate enlargement may develop into LUTS, and larger prostates are associated with a benign prostatic enlargement (BPE), which triggers the risk of developing clinical BPH and urine incontinence. According to the NCBI data, increased adiposity is found to have a positive correlation with prostate volume. In numerous study groups, body weight, body mass index (BMI), and waist circumference have been seen to have a positive correlation with prostate volume. Additionally, epidemiological data shows obesity may raise the need for BPH surgery and BPH treatment.
According to the American Journal of Men's Health (AJMH), in 2019, globally, there were 11.26 million new cases and 1.86 million YLD due to BPH in 2019. The incidence of BPH increased by 105.7%, and YLD increased by 110.6% worldwide during 1990-2019. The absolute incidence and YLD numbers increased considerably worldwide during this period, primarily, due to population increase and aging. The treatment option for BPH includes surgeries such as transurethral resection of the prostate (TURP), open prostatectomy, and minimally invasive treatments such as transurethral needle ablation (TUNA). Benign prostatic hyperplasic devices are used in minimally invasive treatments such as radiofrequency ablation, laser therapy, and implants. Thus, the increase in the prevalence of benign prostatic hyperplasia and related risk factors bolsters the demand for benign prostatic hyperplasic devices.

North America Benign Prostatic Hyperplasic Devices Market Segmentation

The North America benign prostatic hyperplasic devices market is segmented on the basis of product, procedure type, end user, and country. Based on product, the market is segmented into resectoscopes, urology lasers, radiofrequency ablation devices, prostatic stents, and implants. The resectoscopes segment is expected to hold the largest share of the market in 2022. On the other hand, the urology lasers segment is expected to register the highest CAGR during the forecast period.

Based on procedure type, the North America benign prostatic hyperplasic devices market is segmented into transurethral microwave therapy, transurethral resection of the prostate, transurethral needle ablation of the prostate, laser surgery, urolift surgery, and others. The transurethral resection of the prostate segment held the largest market share in 2022, and it is also expected to register the highest CAGR in the market during the forecast period.
Based on end user, the North America benign prostatic hyperplasic devices market is segmented into hospitals, clinics, ambulatory surgical centers, and others. The hospital segment held the largest market share in 2022, while the clinics segment is expected to register the highest CAGR during the forecast period.
Based on country, the North America benign prostatic hyperplasic devices market is segmented into the US, Canada, and Mexico. In 2022, the US held the largest market share, and it is further expected to register the highest CAGR during the forecast period.

KARL STORZ SE & Co. KG; Olympus Corporation; Boston Scientific Corporation; Teleflex Incorporated; Richard Wolf GmbH; Urologix, LLC; OmniGuide Holdings, Inc.; and Convergent Laser Technologies are among the leading companies in the North America benign prostatic hyperplasic devices market.